Rethinking Patient Selection for Addressing Unique Toxicity Challenges From ADC Therapy – Balancing Risk & Access
Time: 1:02 pm
day: Pre-Conference Workshop Day
Details:
Current ADC trials often exclude high-risk patients due to concerns about toxicity, but is this the best approach? This session will explore how we can better predict, manage, and personalize ADC-related toxicities rather than defaulting to exclusion.
Join this workshop to discuss topics such as:
Who is at higher risk of ADC toxicity?
- Understanding the role of clinical characteristics, pre-existing conditions, and biomarker-driven patient selection in predicting adverse events. Examples include: Patients with pre-existing lung disease and ADC-induced interstitial lung disease (ILD)
- Ocular toxicity risks in multiple myeloma patients receiving BCMA-targeting ADCs
Managing toxicity without eliminating patients from treatment
- Industry-wide, patients with risk factors are often excluded from trials. But should we:
- Implement risk-mitigation strategies (e.g. pre-treatment, monitoring, dose adjustments) instead?
- Develop guidelines for overlapping toxicities, such as ocular surface damage due to prior cancer therapies?
Moving toward a patient-first approach to ADC development
- Can the industry harmonize how toxicity is factored into patient selection? Rather than focusing on which ADC lacks a certain toxicity, how can we optimize how to manage different toxicities across ADC classes?
